Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Qure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting ...

The first-ever platform trial for ALS tested four drugs simultaneously, creating a faster path to finding treatments for a ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) da ...

Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including ...

Phosphorylated tau 217 better detected Alzheimer’s disease pathology across a range of neurodegenerative syndromes compared ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

The company will discontinue development of its original ALS gene therapy candidate VY9323 amid toxic effects in nonhuman ...